A combination of factors contribute to the difference in valuations.
1. It is really hard to make a chemo agent that is massively better than the existing drugs. Bisantrene is not really better than the anthracyclines at killing cancer cells, what makes it special is its safety.
2. Precision Oncology drugs tend to have lower toxicities and more “amazing" results. Keytruda is a good example of this - sure it only works in a subset of patients, but when it does work it can actually cure the patient. You can be weeks from dying, be given Keytruda, and walk out of the hospital completely cured.
3. You can charge higher prices for precision oncology drugs. Price matters.
4. Precision Oncology is seen as the future of oncology. Everyone wants to own the next hot thing and investors are no different to anyone else.
Ann: Change in substantial holding, page-71
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |